ConvaTec selects Veeva Vault CDMS for study of biomarkers in wound infections

Veeva Systems announced that ConvaTec, a global medical products company providing therapies focused on the management of chronic disease, has selected  Veeva Vault CDMS , which will provide electronic data entry ( EDC ),  coding  and  data cleaning  for its upcoming study on wound infection detection.

ConvaTec and its partners have developed a new infection biomarker detection technology based on the combined measurement of the following three biomarkers: wound pH, and the activity of host enzymes, human neutrophil elastase (HNE) and myeloperoxidase (MPO). This proof of concept study will explore the efficacy of a novel combination of biomarkers, pH, HNE and MPO, in detecting wound infection.

One of the secondary objectives of the assay is to explore the relationship between molecular microbiological analysis of swab samples and wound biopsies with the biomarkers pH, HNE and MPO.

This is a multi-center international analytical performance study that is expected to take approximately 20 weeks and aims to recruit between 75 and 90 subjects.

Veeva MedTech  is proud to support companies like ConvaTec with Vault CDMS, a unified data management solution for capturing, cleaning and encoding clinical data.

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence and customer success, Veeva has more than 1,100 customers, from the world's largest pharmaceutical companies to emerging biotechnology companies. As a public benefit company, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders and the industries it serves.